Form 4: BioAtla Director Susan Moran Acquires 16,500 Shares of Common Stock
SEC Form 4 Filing
Director Susan Moran acquired 16,500 shares of BioAtla, Inc. common stock through a restricted stock unit award.
Summary
- On June 13, 2024, Susan Moran, a director of BioAtla, Inc., acquired 16,500 shares of common stock.
- The acquisition was made through a time-based restricted stock unit (RSU) award.
- The RSU will vest as to 100% of the total number of shares on the earlier of June 13, 2025, or the next Company annual meeting of stockholders, contingent upon continued service.
- Following the transaction, Moran directly owns 28,807 shares of BioAtla common stock.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a routine disclosure of stock acquisition by a director. While insider buying can be seen as positive, this is part of a compensation package.
Positives
- A director's acquisition of company stock can be seen as a positive signal, indicating confidence in the company's future prospects.
Future Outlook
The vesting of the RSU is contingent upon Susan Moran's continued service with BioAtla.
Industry Context
Form 4 filings are a routine part of regulatory compliance for publicly traded companies, providing transparency into the transactions of company insiders.
Key Dates
| Date | Description |
|---|---|
| 06/13/2024 | Date of transaction: Susan Moran acquired 16,500 shares of BioAtla common stock. |
| 06/13/2025 | Vesting date of the restricted stock unit award, contingent on continued service, or the date of the next annual meeting, whichever is earlier. |
| 06/14/2024 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.